Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company

Most CEOs inherit companies and tweak around the margins. Vasant Narasimhan inherited a 250-year-old pharmaceutical giant and blew it up entirely, unlocking $180 billion in shareholder value by turning one conglomerate into four separate companies. The radical restructuring of Novartis offers a masterclass in strategic focus that challenges conventional wisdom about diversification and corporate staying power.

The math behind Narasimhan's decision reveals why even successful conglomerates can destroy value. "The return on capital varies tremendously between a consumer health business, a generics business, a device business, and a pharmaceuticals business," Narasimhan explains. "We were often forced to say we have to sub optimize the pharmaceutical business to invest in the other businesses." This capital allocation problem created a perpetual trade-off where Novartis couldn't fully commit to any single business line. The company was decent at everything but excellent at nothing.

Rather than accept this mediocrity, Narasimhan executed what he calls "a really pretty radical rethink of the company." Novartis exited its consumer health business through a joint venture with GSK, spun off Alcon as a standalone public company, spun off generics unit Sandoz, and sold its Roche stake. The result: four focused companies where there was once one sprawling conglomerate. The stock market's response validated the strategy immediately, with the combined value of all entities reaching nearly $180 billion more than the original consolidated company was worth.

This breakup enabled something more valuable than financial engineering. By focusing purely on biopharmaceuticals, Novartis could finally invest properly in platform technologies that require massive, sustained capital commitments. The company is now betting big on radioligand therapies and cell/gene treatments, areas where diversified competitors struggle to match the necessary investment levels. Platform technologies in pharma work like software platforms in tech: high upfront costs but exponential returns once the infrastructure is built.

The AI revolution in drug discovery provides the clearest example of how focus pays dividends. Six years ago, Novartis made uncertain bets on artificial intelligence for drug development. Today, Narasimhan reports that "3,000 scientists on the Foundry platform" use AI models "to extract data that used to take six months and now it takes minutes." This isn't incremental improvement; it's a fundamental acceleration of the research process that would have been impossible to achieve while managing unrelated business units.

Yet Narasimhan tempers the AI hype with realistic timelines. While venture capitalists and tech entrepreneurs promise AI-generated drugs within two years, he points out that "the first purely AI generated candidate, by definition, cannot come out the other end for ten, well, eight to ten years." The drug development process involves regulatory approval cycles that no algorithm can compress. Novartis is working with Isomorphic Labs on previously "undruggable targets" using AlphaFold three, but these partnerships represent long-term bets on scientific capability rather than near-term revenue opportunities.

The broader lesson extends beyond pharmaceuticals to any industry facing technological disruption. Narasimhan's strategy suggests that companies should choose between being diversified defensive players or focused offensive innovators. The middle ground, trying to be both, often produces the worst outcomes. Diversification might provide stability, but it also prevents the concentrated investment required to lead in emerging technologies.

For other executives considering similar transformations, Narasimhan's experience suggests three key insights. First, the market will reward strategic focus even when it means accepting higher volatility. Second, platform investments require sustained commitment that conglomerates struggle to provide. Third, breaking up successful companies isn't admission of failure but recognition that different businesses require different capabilities.

The next test for Narasimhan's strategy comes in execution. Spinning off divisions is the easy part; building world-class capabilities in radioligand therapies and cell/gene treatments while integrating AI across the entire research process represents a much harder challenge. But the early results suggest that sometimes the best way to honor a company's 250-year legacy is to abandon everything it used to be.